Literature DB >> 23462696

Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program.

Thomas H Zytkovicz1, Inderneel Sahai, Amii Rush, Adedoyin Odewale, Donna Johnson, Eileen Fitzgerald, Deborah Britton, Roger B Eaton.   

Abstract

OBJECTIVE: The objective of this study is to develop an isotope dilution liquid chromatography tandem mass spectrometry assay to screen for hepatorenal tyrosinemia (HT) from newborn filter paper samples using pooled extracts to increase high throughput screening. DESIGN AND METHODS: Succinylacetone (SUAC), the marker for HT, was extracted from dried blood spots with the formation of the hydrazone derivative of SUAC; up to eight sample extracts were pooled and the SUAC-derivative was analyzed by mass spectrometry methods with an injection-to-injection time of one minute. If any pooled sample extract screened positive, then the samples comprising the pooled sample were assayed individually.
RESULTS: Two newborn infants were identified with high levels of SUAC (7 & 23μM) and later confirmed to have HT. Three older children whose initial filter paper samples were taken at 195days to 614days of age with elevated SUAC (range 4.9-5μM) were identified; one of the three had clinical signs of HT and was placed on treatment (diagnosis of the other two are unavailable).
CONCLUSION: MS/MS analysis of pooled dried blood sample extracts permits sensitive, reduced instrumental analytical time and increase high throughput screening for HT.
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462696     DOI: 10.1016/j.clinbiochem.2013.02.002

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.

Authors:  Víctor R De Jesús; Barbara W Adam; Daniel Mandel; Carla D Cuthbert; Dietrich Matern
Journal:  Mol Genet Metab       Date:  2014-07-17       Impact factor: 4.797

2.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

Review 3.  Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.

Authors:  Chris Stinton; Julia Geppert; Karoline Freeman; Aileen Clarke; Samantha Johnson; Hannah Fraser; Paul Sutcliffe; Sian Taylor-Phillips
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

4.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.